Investors

Symbol: IRME

Designs and develops devices utilizing spectrographic usability medical devices based on the combination of Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company was founded in 2012 and is headquartered in Rosh Pina, Israel.

Press Release

IR-Med files Provisional Patent Application Covering Additional Features of its PressureSafe Device for Early Detection of Pressure Injuries

IR-Med To Initiate Useability Study of its PressureSafe Device

IR-MED Names Moshe Gerber as New CEO

IR-Med Announces $3.2 Million Private Placement

Following Its Recent Annual Updates: IR-Med Announces OTCQB Up-listing: “A Significant Achievement for the Company”

IR-Med to Announce 2022 Goals: Anticipated POC Results, File for FDA Clearance and up Listing to the OTCQB

Financial Statments

August 15, 2022
10-Q - Period Ending 06/30/22
May 16, 2022
10-Q - Period Ending 03/31/22
March 31, 2022
10-K - Period Ending 12/31/21
November 15, 2021
10-Q - Period Ending 09/30/21
August 29, 2021
Q2 2021 - Quarterly Report
March 31, 2021
Q1 2021 - Quarterly Report